Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
A 48 week, randomized, open-label, two arm study to compare the efficacy, safety and
tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1
infected patients started at 2-6 weeks after initiating rifampicin containing
antituberculosis therapy.
Phase:
Phase 2
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborators:
Bamrasnaradura Infectious Diseases Institute Central General Chest Institute Chiang Rai Hospital King Chulalongkorn Memorial Hospital Labor and Welfare other sponsors:Japanese MOPH Thai GPO Thai MOPH The Research Institute of Tuberculosis (Japan)